#Botanix is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025 issue of the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The article presents pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies that formed the basis for US Food and Drug Administration approval of Sofdra.
Click here to read the article.
Botanix Pharmaceuticals has been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors. The interview with CEO, Dr Howie McKibbon includes in-depth look at Botanix and its fulfilment platform, commercialization strategies, company history, and an update on the launch of Sofdra™ (sofpironium) gel, 12.45% in the US.
Botanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).
Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation of Sofdra™, as well as other platform expansion opportunities. H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction.
